Unprecedented surrogate biomarkers are replacing clinical outcomes to secure accelerated drug approvals.
To expedite market access for paradigm-shifting therapies, regulatory agencies are accepting deep molecular markers or lifestyle-management surrogates rather than demanding traditional survival and functional endpoints.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA granted accelerated approval based on a surrogate, lifestyle-management endpoint (reducing raw cornstarch requirements) rather than definitive clinical metrics.
The FDA utilized an early molecular biomarker of cell preservation to accelerate the approval of a critical pediatric autoimmune therapy.
The drug secured accelerated approval based entirely on the surrogate biomarker of proteinuria reduction rather than clinical outcomes.
The first-of-its-class multiple myeloma therapy secured accelerated approval based on a highly precise biological surrogate endpoint instead of traditional survival metrics.
The FDA cleared a first-in-class cancer therapy using a deep molecular clearance biomarker rather than waiting for traditional clinical progression-free survival outcomes.